SCHEMBL1591982

SCHEMBL1591982

C1CN2CCNNC2CN1

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.39
TAAR1 Q96RJ0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4247654 0.84
SCHEMBL4077331 0.75
SCHEMBL8694678 0.71 HTR6 (0.39) HTR6TAAR1
Hydrochloric Acid SCHEMBL6632484 0.69 HTR6 (0.62) HTR6TAAR1
SCHEMBL20651315 0.69
SCHEMBL3383922 0.67 HTR6 (0.35) HTR6TAAR1
SCHEMBL1591800 0.67 HTR6 (0.35) HTR6
SCHEMBL337087 0.66 HTR6 (0.65) HTR6TAAR1
SCHEMBL4067540 0.65 HTR6 (0.42) HTR6
SCHEMBL19005858 0.64 HTR6 (0.32) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3315499-B1 Crystal of (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide EISAI R&D MAN CO LTD (JP) 2021-04-07 EP disclosed
CN-107614504-B Crystals of carboxamide compound 卫材R&D管理有限公司 2019-12-24 CN disclosed
US-10259817-B2 Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-04-16 US disclosed
US-10221183-B2 2019-03-05 US disclosed
US-20180141950-A1 Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide EISAI R&D MANAGEMENT CO., LTD. (JP) 2018-05-24 US disclosed
EP-3315499-A1 CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2018-05-02 EP disclosed
EP-3088401-A1 (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2016-11-02 EP disclosed
CN-105440037-A Preparation method for 1,4,5,8-tetranitro-1,4,5,8-tetraazabicyclo[4.4.0]decane UNIV NANJING SCIENCE & TECH 2016-03-30 CN disclosed
US-9193734-B2 Alpha helix mimetics and methods relating thereto PRISM PHARMA CO., LTD. (JP) 2015-11-24 US disclosed
US-9174998-B2 (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2015-11-03 US disclosed
US-20150175615-A1 (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound PRISM PHARMA CO., LTD. (JP) 2015-06-25 US disclosed
US-20130267482-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM PHARMA CO., LTD. (JP) 2013-10-10 US disclosed
US-8455488-B2 Alpha helix mimetics and methods relating thereto PRISM BIOLAB CORPORATION (JP) 2013-06-04 US disclosed
US-20110092459-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CORPORATION (JP) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267482-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO COL1A1, PLOD3, THPO HTR6 1543/4885TAAR1 4328/4885
US-10221183-B2 NT5C, HTR2C, HTR3C HTR6 49/4885TAAR1 856/4885
US-20110092459-A1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO COL1A1, PLOD3, THPO HTR6 1543/4885TAAR1 4328/4885
US-10259817-B2 Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide NT5C, HTR2C, HTR1D HTR6 22/4885TAAR1 662/4885
US-20150175615-A1 (6S,9aS)-N-Benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-(methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound WNT1, WNT3A, WNT3 HTR6 79/4885TAAR1 3290/4885
US-20180141950-A1 Crystal (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide NT5C, HTR2C, HTR1D HTR6 22/4885TAAR1 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.